The risk of venous thromboembolic disease associated with adjuvant hormone therapy for breast carcinoma: a systematic review.

摘要: BACKGROUND Tamoxifen therapy for patients with breast carcinoma is perceived as an independent risk factor venous thromboembolic events (VTE), but the associated other adjuvant therapies less well recognized. METHODS The authors conducted a computerized PubMed literature search English-language articles published between January 1966 and December 2003. Studies were analyzed regard to trial design, staging, agent, definition of VTE outcomes, method case ascertainment, presence concomitant factors. RESULTS Accurate determination rates was impaired by universal lack routine assessments asymptomatic VTE. Therefore, only symptomatic could be derived. The increased twofold threefold during tamoxifen or raloxifene use chemoprevention. It remains unknown whether further in women inherited hypercoagulable states. In setting early-stage carcinoma, both anastrozole use. Such appeared lower, albeit not negligible, anastrozole. Significant methodologic limitations all available studies advanced-stage precluded true different hormonal agents made it nearly impossible compare drugs. CONCLUSIONS All used chemoprevention appear increase Available data insufficient support any assumptions that newer forms hormone manipulation are safer than advanced carcinoma. Cancer 2004. © 2004 American Society.